Gastrointestinal stromal tumors (GISTs) represent 1% of alimentary tract neoplasms. Up to 90% of GISTs are driven by activating mutations in tyrosine kinase KIT or PDGFRα genes. Imatinib mesylate is a tyrosine kinase inhibitor that has recently been used in a neoadjuvant role for locally advanced GIST. Pathologic complete response (pCR) to imatinib, however, is rare and may be limited to patients with certain mutations. We report on a 71-year-old woman with a large advanced gastric GIST near the gastroesophageal junction initially involving the pancreas, spleen, adrenal, and aortic wall. The tumor harbored a KIT exon 11 deletion mutation in codon 558, which predicts a favorable response to imatinib. After 6 months of neoadjuvant imatinib therapy, the tumor was downstaged to allow partial gastric resection without the need for total gastrectomy reconstruction. The patient underwent partial gastrectomy, distal pancreatectomy, and splenectomy, and histologic examination showed a margin-negative resection with a near-pCR, with <5% viable tumor. Prolonged neoadjuvant therapy was undertaken based on the prognostic significance of a KIT exon 11 deletion mutation in codon 558, which facilitated an R0 resection while minimizing the surgical extent of the resection. A near-pCR of a large gastric GIST after neoadjuvant imatinib therapy remains a rare occurrence. Molecular testing should be undertaken before neoadjuvant therapy, because specific mutations can identify patients who will respond to imatinib and those likely to achieve significant downstaging and pCR.
Gastrointestinal stromal tumors (GISTs) are a class of subepithelial mesenchymal neoplasms typically arising in the alimentary tract from the interstitial cells of Cajal, and represent 1% of primary gastrointestinal tract cancers. Up to 90% of GISTs are driven by an activating mutation in the KIT or PDGFRα genes, which encode tyrosine kinase proteins. 1 KIT mutations are most common, and molecular analysis has identified a number of mutation locations, including exons 9, 11, 13, and 17. Imatinib mesylate, a tyrosine kinase inhibitor, has shown efficacy in advanced and metastatic GIST. showing its ability to reduce the morbidity associated with surgical resection and facilitate an R0 resection in up to 91% of patients. 3, 4 Despite this success, pathologic complete response (pCR) to neoadjuvant imatinib remains rare, and the indications and duration of therapy are less well-defined. 5 Recent data suggest that specific mutations giving rise to GIST appear to have prognostic significance, primarily through responsiveness to imatinib therapy, with KIT exon 11 mutations showing a superior response. 6 This report describes a patient with locally advanced gastric GIST harboring a KIT exon 11 mutation who experienced a near-pCR to neoadjuvant imatinib.
Case Presentation
A 71-year-old woman with a medical history of chronic obstructive pulmonary disease on 3 liters of home oxygen presented to her local hospital with a 2-day history of melena and dizziness. She was noted to have anemia, with a hemoglobin level of 7.9 g/dL. She was initially treated with proton pump inhibitors, received 2 units of packed RBCs, and underwent upper and lower endoscopy. Upper endoscopy revealed erosive gastritis and a submucosal mass. She was referred to the University of Pittsburgh Medical Center for an endoscopic ultrasound, which revealed an 8.7-cm gastric cardia tumor. Biopsy results revealed spindle cell-type GIST with immunohistochemistry staining positive for C-kit and DOG-1, and negative for desmin and S-100. CT of the chest, abdomen, and pelvis revealed an 11.3 x 9.8-cm lobular mass arising from the posterior stomach abutting the superior pole of the spleen, distal pancreas, adrenal gland, and lateral aortic wall with features of central necrosis ( Figure 1 ). No suspicious adenopathy or evidence of metastasis was present. The absence of metastasis was confirmed with PET/CT ( Figure 2 ). Molecular analysis of the biopsy tissue revealed a KIT exon 11 p.E544_K558del mutation.
After multidisciplinary discussion, the patient was started on 400 mg/d of oral imatinib with plans for 4 to 6 months of neoadjuvant therapy to maximize tumor response in the presence of a KIT exon 11 K588 deletion mutation. CT of the abdomen and pelvis at 2 months after imatinib initiation showed a treatment response, with an interval decrease in tumor size to 7.8 x 6.0 cm and a decrease in tumor density. Imaging at 4 months showed continued interval decrease in tumor size. At 6 months after initiation of imatinib, the tumor no longer abutted the adrenal gland or lateral aortic wall, and measured 7.5 x 5.7 cm in maximal diameter ( Figure 3 ). The patient had tolerated neoadjuvant therapy well, with minor side effects including anemia requiring blood transfusion, myalgias, facial rash, anorexia, and mild elevation of lactate dehydrogenase level, with no serious adverse events. Given the good response to neoadjuvant therapy, she was offered surgical resection. Imatinib was stopped for 3 weeks preoperatively.
Exploratory laparotomy showed that the mass involved the gastric cardia, distal pancreas, and splenic hilum. After dissection and mobilization of the stomach and intra-abdominal esophagus, it became apparent that the mass could be resected by partial (wedge) gastrectomy without need for reconstruction. Furthermore, the tumor did not involve the aorta or left adrenal gland. A partial gastrectomy was performed with en bloc distal pancreatectomy and splenectomy. Her postoperative course was uneventful; an upper gastrointestinal series obtained on postoperative day 4 showed no leak from the gastric resection line. She was discharged home on postoperative day 7, and will continue imatinib, 400 mg orally for at least 3 years.
Pathologic examination of the resected specimen revealed a 6.8-cm predominantly nonviable GIST with metaplastic ossification (Figure 4 ). All surgical margins were negative. The mitotic index was 0 mitoses per 5 mm 2 . Only focal areas of viability were demonstrated by positive immunohistochemistry staining of C-kit, DOG-1, and CD34 in <5% of 
Discussion
A pCR is a rare occurrence for a large gastric GIST. Our report presents a near-pCR of a gastric GIST harboring a KIT exon 11 K588 deletion mutation after prolonged treatment with imatinib. Based on the molecular profile of the tumor, prolonged neoadjuvant therapy was undertaken to achieve 2 specific objectives. First, given the patient's comorbidities, we aimed to sufficiently downstage the tumor to avoid a total gastrectomy, particularly because initial imaging showed the tumor in proximity to the gastroesophageal junction, likely requiring a total gastrectomy. Second, initial imaging also showed abutment of the aortic wall, increasing the likelihood of a margin-positive resection with upfront surgery. Prolonged neoadjuvant therapy sufficiently shrank the tumor off the aorta and facilitated an R0 resection. Despite the large tumor size, identification of a KIT exon 11 deletion mutation including codon 558 predicted a favorable response to imatinib, enabling a margin-negative resection with a potentially less morbid operation.
Since the first report of GIST response to imatinib, this agent has revolutionized the therapeutic approach to this disease, which previously had no effective therapies. 7 Despite this, pCR after neoadjuvant imatinib remains rare ( Table 1 ). The first report was in 2003 by Scaife et al 8 of 2 patients with pCR from 126 patients treated with imatinib for unresectable GIST. Since then, pCR has been reported in case reports or small series ranging from 1% to 16% of resected tumors. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Many of the reported pCRs, however, occurred in patients with colorectal or pelvic GIST. 11, 12, 18 Molecular features have a significant impact on prognosis in GISTs, particularly with regard to imatinib response. 1 Mutations in the KIT gene are the most common, accounting for 80% to 85% of GIST mutations, with PDGFRα mutations representing 5% to 10% of mutations. The remaining mutations have been termed wild-type; however, SDH and BRAF mutations have been identified among these tumors. Within the KIT gene, exon 11 mutations are most common, accounting for 70% of cases, whereas exon 9 mutations account for 10% to 15%. Patients with exon 9 mutations should be considered for imatinib dose escalation to 800 mg daily. These mutations may be less responsive to imatinib, and higher dosing regimens have been associated with improved progression-free survival in advanced GIST. 6 Exon 13, 14, and 17 mutations have also been identified, representing 1% to 2% of cases, respectively.
Further differences in prognosis and response have been identified based on the type of KIT exon 11 mutation. Deletion mutations exhibit aggressive behavior compared with other types of mutations, particularly deletions in the 557/558 codons, as seen in our patient. 19 Analysis of the ACOSOG Z9001 trial showed improved recurrence-free survival among patients receiving imatinib with KIT exon 11 deletions compared with those with point mutations or insertions of exon 11 at a median follow-up of 74 months. 6 To our knowledge, all reported mutations among patients with pCR after neoadjuvant imatinib involve KIT exon 11 mutations, including our case. 11, 14, 20 Of the specific mutations identified in prior reports, each was a deletion. 14, 20 Thus, molecular analysis may prove useful in delineating the potential for pCR and clinical response to imatinib.
A neoadjuvant approach to locally advanced GIST is being increasingly used; however, the indications and optimal duration of neoadjuvant imatinib are not well-defined. In this case report, a prolonged neoadjuvant strategy was successful in minimizing surgical morbidity while maximizing the potential for an R0 resection. Early phase II trials used neoadjuvant therapy for 2 to 3 months, and reported R0 resection rates of 67% to 77% 21, 22 ; however, a more recent phase II trial treated patients for 6 to 9 months and reported an R0 resection rate of 91%. 3 Several retrospective series have also reported on outcomes after longer neoadjuvant therapy with imatinib, 4, 9 with evidence suggesting that the optimal response may be between 7 to 12 months. 4, 9, 23 Neoadjuvant imatinib duration in patients with a reported pCR (including the current report) was a mean of 11.3 months, with a range of 6 to 35 months. 8, [11] [12] [13] [14] [15] 17, 20, 24 However, in some reports it is unclear whether imatinib served as true neoadjuvant therapy (with the intent for resection made upfront at treatment initiation) or as definitive therapy in patients with unresectable disease who eventually underwent resection after significant downstaging. 8 Current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for GIST recommend neoadjuvant therapy be considered if it could reduce surgical morbidity through downstaging the tumor. 25 NCCN Guidelines note that therapy may require treatment for 6 months to achieve maximal response, and recommend mutation testing to ensure a favorable genotype for imatinib response. Given the promising results of small series and phase II trials, larger trials are warranted to further elucidate the optimal neoadjuvant regimen for advanced GIST.
Conclusions
We report the near-pCR of a large gastric GIST after neoadjuvant imatinib therapy. This remains a rare occurrence after GIST resection and was facilitated by prolonged imatinib therapy in the presence of a KIT exon 11 K558 mutation. This case report highlights the importance of molecular testing before neoadjuvant imatinib for GIST, because certain mutations can identify patients more likely to benefit from significant tumor downstaging and pathologic response.
